GlassScriptPhysician profile
Bingru Xie
NPI 1487802690
$6,373.58
in general payments reported to CMS, 2019-2025
16 companies · $508 in 2025
The $508 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.54 · 2020: $2,320 · 2021: $3,066 · 2022: $129 · 2023: $97.77 · 2024: $200 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $5,568.44 | 2019-2025 | Livdelzi |
| Abbvie INC. | $136.73 | 2021-2025 | Creon, Linzess |
| Phathom Pharmaceuticals, INC. | $127.20 | 2024-2025 | Voquezna |
| Vivus LLC | $114.44 | 2022-2025 | Pancreaze, Qsymia |
| Intercept Pharmaceuticals, INC. | $97.40 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.57 | 2019-2024 | Xifaxan, Plenvu |
| Braintree Laboratories, INC. | $79.48 | 2021-2023 | Sutab |
| Madrigal Pharmaceuticals | $55.73 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $17.75 | 2023 | Rebyota |
| Aimmune Therapeutics, INC. | $16.85 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $14.08 | 2024 | Givlaari |
| Janssen Biotech, INC. | $14.05 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.90 | 2022 | |
| Daiichi Sankyo INC. | $12.43 | 2021 | |
| Redhill Biopharma INC. | $12.28 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bingru Xie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.